中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

79 records (took 0.024 seconds)

    Synthetic composition for treating metabolic disorders
    32.
    发明授权
    Synthetic composition for treating metabolic disorders 有权

    公开(公告)号：US11890293B2

    公开(公告)日：2024-02-06

    申请号：US17141772

    申请日：2021-01-05

    Applicant: GLYCOM A/S

    Inventor： Bruce McConnell ,  Louise Kristine Vigsnæs ,  Emma Elison

    IPC: A61K31/702 ,  A61P3/10 ,  A61K9/00 ,  A61K9/20

    CPC classification number: A61K31/702 ,  A61K9/0053 ,  A61K9/0095 ,  A61K9/2054 ,  A61P3/10

    Abstract: A method includes selecting a non-infant patient having an obesity-related metabolic disorder and being diagnosable with one or more of obesity, obesity-induced pre-diabetes, and obesity-induced type 2 diabetes. The method further includes selecting an effective amount of one or more human milk oligosaccharides (HMOs) selected from: fucosylated HMOs 2′-fucosyllactose (2′-FL), 3-fucosyllactose (3-FL), lacto-N-fucopentaose I (LNFP-I), and difucosyllactose (DFL); non-fucosylated HMOs lacto-N-tetraose (LNT), lacto-N-neotetraose (LNnT), 3′,6-disialyllacto-N-tetraose (DSLNT), 6′-sialyllactose (6′-SL), and 3′-sialyllactose (3′-SL); and mixtures thereof. The method further includes increasing the relative abundance of Bifidobacterium adolescentis in the non-infant patient by administering the selected effective amount of the selected one or more HMOs and improving in the non-infant patient at least one condition selected from increased insulin sensitivity, reduced insulin resistance, improved gut barrier function, and reduction of metabolic inflammation. In various examples, the method includes increasing levels of at least one glucagon-like peptide.

    SYNTHETIC COMPOSITION FOR TREATING METABOLIC DISORDERS
    33.
    发明申请
    SYNTHETIC COMPOSITION FOR TREATING METABOLIC DISORDERS 有权

    公开(公告)号：US20230119720A1

    公开(公告)日：2023-04-20

    申请号：US18082793

    申请日：2022-12-16

    Applicant: GLYCOM A/S

    Inventor： Emma Elison ,  Bruce McConnell ,  Thierry Hennet ,  Louise Kristine Vigsnæs

    IPC: A61K31/702 ,  A61K31/7012 ,  A61K31/7004 ,  A61K9/00

    Abstract: A method for treating metabolic disorders includes determining a treatment group comprising obese non-infant humans; formulating a composition comprising one or more synthetic non-fucosylated human milk oligosaccharides (HMOs) selected from lacto-N-tetraose (LNT), lacto-N-neotetraose (LNnT) and/or 2′-fucosyllactose (2′-FL), 3-fucosyllactose (3-FL), difucosyllactose (DFL), and lacto-N-fucopentaose I (LNFP-I), that are effective for: increasing in the gastrointestinal microbiota of a non-infant human during a treatment period, the relative abundance of Bifidobacterium adolescentis and reducing a precursor condition for a metabolic disorder associated with development of one or more of obesity-induced pre-diabetes and type 2 diabetes, the precursor condition selected from gut permeability, metabolic endotoxemia, low-grade metabolic inflammation, and body fat percentage; and reducing the precursor condition in at least one non-infant human in the treatment group by providing the composition to the at least one non-infant human during the treatment period.

    SYNTHETIC COMPOSITION FOR TREATING METABOLIC DISORDERS
    39.
    发明申请
    SYNTHETIC COMPOSITION FOR TREATING METABOLIC DISORDERS 有权

    公开(公告)号：US20210196735A1

    公开(公告)日：2021-07-01

    申请号：US17141772

    申请日：2021-01-05

    Applicant: GLYCOM A/S

    Inventor： Bruce McConnell ,  Louise Kristine Vigsnæs ,  Emma Elison

    IPC: A61K31/702 ,  A61K9/00 ,  A61K9/20

    Abstract: A method includes selecting a non-infant patient having an obesity-related metabolic disorder and being diagnosable with one or more of obesity, obesity-induced pre-diabetes, and obesity-induced type 2 diabetes. The method further includes selecting an effective amount of one or more human milk oligosaccharides (HMOs) selected from: fucosylated HMOs 2′-fucosyllactose (2′-FL), 3 -fucosyllactose (3-FL), lacto-N-fucopentaose I (LNFP-I), and difucosyllactose (DFL); non-fucosylated HMOs lacto-N-tetraose (LNT), lacto-N-neotetraose (LNnT), 3′,6-di sialyllacto-N-tetraose (DSLNT), 6′-sialyllactose (6′-SL), and 3′-sialyllactose (3′-SL); and mixtures thereof. The method further includes increasing the relative abundance of Bifidobacterium adolescentis in the non-infant patient by administering the selected effective amount of the selected one or more HMOs and improving in the non-infant patient at least one condition selected from increased insulin sensitivity, reduced insulin resistance, improved gut barrier function, and reduction of metabolic inflammation. In various examples, the method includes increasing levels of at least one glucagon-like peptide.

Patent Agency Ranking